Fennec turns profitable on 73% revenue growth; Cipla settlement extends exclusivity to 2033

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~1 min read

Key Changes

• high

  Q1 2026 net income of $201K vs. $1.2M loss in Q1 2025, marking first quarterly profit. Revenue grew 73% YoY to $15.1M driven by deeper PEDMARK market penetration in pediatric and AYA oncology segments.

  MD&A: Financial Results verify on EDGAR →
• high

  Cipla patent settlement bars generic entry until September 2033, extending market exclusivity 4 years beyond orphan drug protection (expires 2029) and removing litigation uncertainty.

  MD&A: Cipla Settlement verify on EDGAR →
• high

  Cash position strengthened 77% to $40.2M and working capital up 66% to $57.3M, reflecting profitable operations and zero debt following full Petrichor note repayment in Q4 2025.

  MD&A: Liquidity verify on EDGAR →